ROME, Sept 23 (Bernama-GLOBE NEWSWIRE) — Angelini Pharma, part of the privately owned Angelini Industries, and Sovargen, a South-Korean biotechnology company, announced today that they signed an exclusive global option agreement for the development and commercialization of Sovargen’s innovative brain health asset SVG105.
Under the terms of the agreement, Angelini Pharma and Sovargen will collaboratively lead the pre-clinical development efforts for SVG105 and, following an initial option period, Angelini Pharma will have the right to advance the compound into clinical development and commercialization outside of the Republic of Korea, China, Hong Kong, Macau and Taiwan. SVG105 is a potentially first-in-class anti-sense oligonucleotide technology to target mTOR (mammalian target of rapamycin) pathways. mTOR is a genetically validated target for a number of brain health disorders, including drug-resistant childhood epilepsy.i